⚡ Flash Summary
Abbott Laboratories (Pakistan) Limited reported a strong performance for the quarter ended September 30, 2025. Sales increased significantly compared to the same period last year, driving higher profitability. Net profit for the period grew, supported by effective cost management and increased operational efficiency. The company’s earnings per share (EPS) also saw a notable rise, reflecting improved shareholder value.
📌 Key Takeaways
- 📈 Sales-Net increased to PKR 56.23 billion for the nine months ended September 30, 2025, compared to PKR 49.56 billion in 2024.
- 🌍 Export sales grew slightly to PKR 2.32 billion from PKR 2.29 billion year-over-year.
- 💰 Gross profit rose to PKR 19.34 billion for the nine months, up from PKR 14.07 billion in the previous year.
- 📊 Basic and diluted earnings per share increased to PKR 54.81 from PKR 40.34 year-over-year.
- 📉 Finance costs decreased to PKR 55.36 million from PKR 18.59 million.
- 🏢 Profit before taxation significantly improved to PKR 9.16 billion from PKR 6.04 billion.
- 💸 Net profit for the period jumped to PKR 5.37 billion from PKR 3.95 billion.
- 🧪 Local sales increased to PKR 53.91 billion for the nine months, compared to PKR 47.27 billion in 2024.
- ⚠️ Selling and distribution expenses increased to PKR 8.50 billion from PKR 7.12 billion.
- ✅ Other income increased to PKR 603.34 million from PKR 541.11 million.
- 🏦 Cash and cash equivalents increased to PKR 9.01 billion as of September 30, 2025, from PKR 6.18 billion at the end of 2024.
🎯 Investment Thesis
Based on the strong financial results and improved profitability, a BUY recommendation is warranted. The company’s increased sales, efficient cost management, and strong cash position make it an attractive investment. A price target of PKR 65 per share is set, with a time horizon of 12 months, assuming the company continues to maintain its growth trajectory and manage its operational efficiencies.
Disclaimer: AI-generated analysis. Not financial advice.